Advances of fulvestrant in treatment of advanced breast cancer in hormone receptor-positive postmenopausal women
10.3969/j.issn.1007-3969.2016.05.021
- VernacularTitle:氟维司群治疗绝经后激素受体阳性晚期乳腺癌的研究进展
- Author:
Jiayu WANG
;
Binghe XU
- Publication Type:Journal Article
- Keywords:
Fulvestrant;
Postmenopausal women;
Hormone receptor positive;
Advanced breast cancer
- From:
China Oncology
2016;26(5):471-475
- CountryChina
- Language:Chinese
-
Abstract:
Endocrine therapy targeting estrogen pathway is one of the ifrst-line treatment choices of advanced breast cancer. Fulvestrant is a pure estrogen antagonist that blocks and downgrades estrogen receptor, which makes it effective in the treatment of progression after prior endocrine therapy. Fulvestrant 250 mg per month regime was approved for postmenopausal women with hormone-positive advanced breast cancer after progression or recurrence on antiestrogen therapy. Fulvestrant 500 mg per month regime was approved by the EMA and the US FDA in the same population based on the CONFIRM trial which proved improved efifcacy and similar tolerance compared with 250 mg regime. Recent trials were focused in the ifrst-line treatment and combination use with other therapeutics. This review discusses the advances of fulvestrant in postmenopausal women with hormone-positive advanced breast cancer.
